The CCK-B antagonist LY288513 blocks the affects of nicotine withdrawal on auditory startle

NeuroReport

Volumn 7, Issue 5, 1996, Pages 1050-1052

  Rasmussen, Kurt ^a   Czachura, Janet F ^a   Kallman, Mary Jeanne ^a   Helton, David R ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Acoustic startle reflex; CCK B antagonists; Cholecystokinin; LY288513; Nicotine withdrawal

Indexed keywords

CHOLECYSTOKININ B RECEPTOR ANTAGONIST; N (4 BROMOPHENYL) 3 OXO 4,5 DIPHENYL 1 PYRAZOLIDINECARBOXAMIDE; NICOTINE;

ACOUSTIC REFLEX; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUDITORY STIMULATION; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RAT; STARTLE REFLEX; SUBCUTANEOUS DRUG ADMINISTRATION; WITHDRAWAL SYNDROME;

ANIMALS; HORMONE ANTAGONISTS; MALE; NICOTINE; PYRAZOLES; RATS; RECEPTORS, CHOLECYSTOKININ; STARTLE REACTION; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0029967399     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-199604100-00019     Document Type: Article

References (26)

1. Hill DR and Woodruff GN. Brain Res 526, 276-283 (1990).
2. Singh L, Field MJ, Hughes J et al. Br J Pharmacol 104, 239-245 (1991).
3. Powell KR and Barrett JE. Neuropeptides 19, 75-78 (1991).
4. Charrier D, Dangoumau L, Puech AJ et al. Psychopharmacology 121, 127-134 (1995).
5. Dawson GR, Rupniak NMJ, Iversen SD et al. Psychopharmacology 121, 109-117 (1995).
6. Helton DR, Berger JE, Czachura JF et al. Pharmacol Biochem Behav in press (1996).
7. Baldwin HA and File SE. Psychopharmacology 97, 424-426 (1989).
8. Costall B, Jones J, Kelly ME et al. Pharmacol Biochem Behav 36, 97-104 (1990).
9. Goudie AJ, Harrison AA and Leathley MJ. NeuroReport 4, 295-298 (1993).
10. Martinex JA, Fargeas MJ and Bueno L. Pharmacol Biochem Behav 41, 461-464 (1992).
11. Rasmussen K, Helton DR, Berger JE et al. Neuroreport 5, 154-156 (1993).
12. Singh L, Field MJ, Vass CA et al. Br J Pharmacol 105, 9-10 (1992).
13. Goudie AJ and Leathley MJ. Psychopharmacology 118, 57-64 (1995).
14. Costall B, Jones J, Kelly ME et al. Pharmacol Biochem Behav 36, 97-104 (1990).
15. Helton DR, Modlin DL, Tizzano JP et al. Psychopharmacology 113, 205-210 (1993).
16. Hughes JR and Hatsukami D. Arch Gen Psychiatry 43, 289-294 (1986).
17. Benwell MEM and Balfour DJK. Psychopharmacology 63, 7-11 (1979).
18. Zhang X, Gong Z-H and Nordberg A. Brain Res 644, 32-39 (1994).
19. Kimura I, Wakasono S and Kimura M. Jpn J Pharmacol 68, 129-132 (1995).
20. Malin DH, Lake JR, Carter VA et al. Psychopharmacology 112, 339-342 (1993).
21. Dourish CT, O'Neill MF, Coughlan J et al. Eur J Pharmacol 176, 35-44 (1990).
22. Balfour DJK and Benwell MEM. Asia Pacific J Pharmacol 8, 153-167 (1993).
23. Rasmussen K and Czachura JF. NeuroReport in press (1995).
24. Benwall MEM and Balfour DJK. Br J Pharmacol 105, 849-856 (1992).
25. Rasmussen K, Czachura JF, Stockton ME et al. J Pharmacol Exp Ther 264, 480-488 (1993).
26. Li D, Simmons RM, Howbert JJ et al. Soc Neurosci Abstr 19, 1547 (1993).